Here's why the Recce (ASX:RCE) share price is rocketing 12% today

The company's latest clinial trial update seems to have excited investors…

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is soaring today. This comes after the pharmaceutical company provided an update on its clinical trial for the treatment of burn wound infections.

At the time of writing, the Recce share price is up 12.21% to 96.5 cents. In comparison, the All Ordinaries (ASX: XAO) is up 0.51% to 7,567.7 points.

What did Recce announce?

The Recce share price is surging after the company reported positive results for its broad-spectrum antibiotic Recce 327 drug.

The phase I/II study assessed the safety and efficacy of Recce 327 against infectious bacteria on burn wounds in patients.

As such, investigators reviewed the findings and noted a visible infection reduction within the first 24 hours of treatment. Patients with acute infected wounds completely recovered, requiring no further treatment. Investigators adopted a shorter five-day treatment protocol for these patients.

Those who had more severe surface area wounds were given a seven-day timeframe, resulting in a similar outcome.

Initially, the trial had been scheduled to run over the 14 days. Two cohorts of patients would either receive Recce 327 daily or three times per week.

Recce advised that the study is ongoing, with further patient enrolment expected by early 2022.

Once the trial is completed, clinicians will review the results and decide upon the best standards of care for future programs. In addition, burn wound specialists will oversee the delivery of Recce 327 via a spray-on formulation.

The trial is being sponsored by the Western Australian government's Department of Health. It is taking place at the Fiona Stanley Hospital (Burns Unit) in Perth.

Commenting on the results fuelling the Recce share price today, CEO James Graham said:

We are pleased with the progress of our lead compound, R327, in patients harbouring serious burn wound infections. This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic. We look forward to updating shareholders of further human clinical data points as this trial progresses.

Recce share price summary

Despite today's euphoric rise, the Recce share price has had a disappointing 12 months, falling by around 20%. When looking at year-to-date, it is hovering around 9% lower.

Based on today's price, Recce presides a market capitalisation of roughly $149.45 million, with approximately 173.79 million shares on issue.

Should you invest $1,000 in Commonwealth Bank Of Australia right now?

Before you buy Commonwealth Bank Of Australia shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Commonwealth Bank Of Australia wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »